Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics (SRPT)
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Sarepta Therapeutics, with a price target of $20.00. The company’s shares closed last Wednesday at $18.97.
According to TipRanks.com, Ulz is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $22.27 average price target, which is a 18.1% upside from current levels. In a report released yesterday, TD Cowen also reiterated a Hold rating on the stock with a $17.00 price target.
See today’s best-performing stocks on TipRanks >>
ACADIA Pharmaceuticals (ACAD)
H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on ACADIA Pharmaceuticals today and set a price target of $37.00. The company’s shares closed last Wednesday at $24.97.
According to TipRanks.com, Ghosh is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $32.50 average price target, implying a 31.9% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $37.00 price target.
